Abstract

In our issue of September 18, we discussed the use of vasoconstrictor drugs in myocardial infarction (Drug Ther. Bull. p. 73), pointing out the theoretical reasons for doubting their advisability, though many clinicians think that noradrenaline is of value. Since then two papers have appeared which reinforce our arguments.